SETTING: Brewelskloof Hospital, Western Cape, South Africa. OBJECTIVES: To verify the perceived increase in rifampicin monoresistant tuberculosis (RMR-TB) in the Cape Winelands-Overberg region and to identify potential risk factors. DESIGN: A retrospective descriptive study of trends in RMR-TB over a 5-year period (2004-2008), followed by a case-control study of RMR and isoniazid (INH) monoresistant TB cases, diagnosed from April 2007 to March 2009, to assess for risk factors. RESULTS: The total number of RMR-TB cases more than tripled, from 31 in 2004 to 98 in 2008. The calculated doubling time was 1.63 years (95%CI 1.18-2.66). For the assessment of risk factors, 95 RMR-TB cases were objectively verified on genotypic and phenotypic analysis. Of 108 specimens genotypically identified as RMR cases, 13 (12%) were misidentified, multidrug-resistant TB. On multivariate analysis, previous use of antiretroviral therapy (OR 6.4, 95%CI 1.3-31.8), alcohol use (OR 4.8, 95%CI 2.0-11.3) and age ≥ 40 years (OR 5.8, 95%CI 2.4-13.6) were significantly associated with RMR-TB. CONCLUSION: RMR-TB is rapidly increasing in the study setting, particularly among patients with advanced human immunodeficiency virus (HIV) disease. Routine drug susceptibility testing should be considered in all TB-HIV co-infected patients, and absence of INH resistance should be confirmed phenotypically if genotypic RMR-TB is detected.
SETTING: Brewelskloof Hospital, Western Cape, South Africa. OBJECTIVES: To verify the perceived increase in rifampicin monoresistant tuberculosis (RMR-TB) in the Cape Winelands-Overberg region and to identify potential risk factors. DESIGN: A retrospective descriptive study of trends in RMR-TB over a 5-year period (2004-2008), followed by a case-control study of RMR and isoniazid (INH) monoresistant TB cases, diagnosed from April 2007 to March 2009, to assess for risk factors. RESULTS: The total number of RMR-TB cases more than tripled, from 31 in 2004 to 98 in 2008. The calculated doubling time was 1.63 years (95%CI 1.18-2.66). For the assessment of risk factors, 95 RMR-TB cases were objectively verified on genotypic and phenotypic analysis. Of 108 specimens genotypically identified as RMR cases, 13 (12%) were misidentified, multidrug-resistant TB. On multivariate analysis, previous use of antiretroviral therapy (OR 6.4, 95%CI 1.3-31.8), alcohol use (OR 4.8, 95%CI 2.0-11.3) and age ≥ 40 years (OR 5.8, 95%CI 2.4-13.6) were significantly associated with RMR-TB. CONCLUSION: RMR-TB is rapidly increasing in the study setting, particularly among patients with advanced human immunodeficiency virus (HIV) disease. Routine drug susceptibility testing should be considered in all TB-HIV co-infectedpatients, and absence of INH resistance should be confirmed phenotypically if genotypic RMR-TB is detected.
Authors: L Sangare; S Diande; S Kouanda; B I Dingtoumda; A Mourfou; F Ouedraogo; I Sawadogo; B Nebie; A Gueye; L T Sawadogo; A S Traore Journal: Ann Afr Med Date: 2010 Jan-Mar
Authors: Alistair D Calver; Alecia A Falmer; Megan Murray; Odelia J Strauss; Elizabeth M Streicher; Madelene Hanekom; Thelma Liversage; Mothusi Masibi; Paul D van Helden; Robin M Warren; Thomas C Victor Journal: Emerg Infect Dis Date: 2010-02 Impact factor: 6.883
Authors: Sangita Malhotra; Victoria J Cook; Joyce N Wolfe; Patrick Tang; Kevin Elwood; Meenu K Sharma Journal: Tuberculosis (Edinb) Date: 2010-01-25 Impact factor: 3.131
Authors: M Sanders; A Van Deun; D Ntakirutimana; J P Masabo; J Rukundo; L Rigouts; K Fissette; F Portaelst Journal: Int J Tuberc Lung Dis Date: 2006-02 Impact factor: 2.373
Authors: M Lutfey; P Della-Latta; V Kapur; L A Palumbo; D Gurner; G Stotzky; K Brudney; J Dobkin; A Moss; J M Musser; B N Kreiswirth Journal: Am J Respir Crit Care Med Date: 1996-02 Impact factor: 21.405
Authors: Prema Gurumurthy; Geetha Ramachandran; A K Hemanth Kumar; S Rajasekaran; C Padmapriyadarsini; Soumya Swaminathan; P Venkatesan; L Sekar; S Kumar; O R Krishnarajasekhar; P Paramesh Journal: Clin Infect Dis Date: 2003-12-19 Impact factor: 9.079
Authors: Alberto Matteelli; Mario Regazzi; Paola Villani; Giuseppina De Iaco; Maria Cusato; Anna Cristina C Carvalho; Silvio Caligaris; Lina Tomasoni; Maria Manfrin; Susanna Capone; Giampiero Carosi Journal: Curr HIV Res Date: 2007-05 Impact factor: 1.581
Authors: Bertin C Bisimwa; Jean B Nachega; Robin M Warren; Grant Theron; John Z Metcalfe; Maunank Shah; Andreas H Diacon; Nadia A Sam-Agudu; Marcel Yotebieng; André N H Bulabula; Patrick D M C Katoto; Jean-Paul Chirambiza; Rosette Nyota; Freddy M Birembano; Eric M Musafiri; Sifa Byadunia; Esto Bahizire; Michel K Kaswa; Steven Callens; Zacharie M Kashongwe Journal: Clin Infect Dis Date: 2021-07-15 Impact factor: 9.079
Authors: Jörg Haupenthal; Yannik Kautz; Walid A M Elgaher; Linda Pätzold; Teresa Röhrig; Matthias W Laschke; Thomas Tschernig; Anna K H Hirsch; Vadim Molodtsov; Katsuhiko S Murakami; Rolf W Hartmann; Markus Bischoff Journal: ACS Infect Dis Date: 2020-09-21 Impact factor: 5.084
Authors: M J Nasiri; S Zamani; A Pormohammad; M M Feizabadi; H R Aslani; M Amin; R Halabian; A A Imani Fooladi Journal: Eur J Clin Microbiol Infect Dis Date: 2017-08-19 Impact factor: 3.267
Authors: A Dramowski; M M Morsheimer; A M Jordaan; T C Victor; P R Donald; H S Schaaf Journal: Int J Tuberc Lung Dis Date: 2012-01 Impact factor: 2.373